JAGUAR HEALTH, INC. (JAGX) Operating Margin
- Operating margin · 12 months: Value -93.10%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -93.10% | Operating income / revenue. Period ending 2026-06-30. $-25.89M ÷ $27.82M × 100 ≈ -93.10% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -25.89M USD | Operating Income (Loss) |
| Revenue | 27.82M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 25.23M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-25.89M | $27.82M | (m) | $25.23M | (m) | -93.10% |
| 2026-03-31 | $-26.30M | $29.57M | (m) | $25.16M | (m) | -88.96% |
| 2025-12-31 | $-45.91M | $11.51M | $97.00K | $24.97M | (m) | -398.82% |
| 2025-09-30 | $-32.82M | $11.79M | (m) | $15.19M | (m) | -278.52% |
| 2025-06-30 | $-32.85M | $11.81M | (m) | $15.57M | (m) | -278.13% |
| 2025-03-31 | $-32.04M | $11.55M | (m) | $15.96M | (m) | -277.33% |
| 2024-12-31 | $-30.83M | $11.69M | (m) | $16.54M | (m) | -263.76% |
| 2024-09-30 | $-30.23M | (m) | (m) | $15.47M | (m) | (m) |
| 2024-06-30 | $-31.76M | (m) | (m) | $17.51M | (m) | (m) |
| 2024-03-31 | $-32.66M | (m) | (m) | $18.13M | (m) | (m) |
| 2023-12-31 | $-34.29M | (m) | (m) | $18.60M | (m) | (m) |
| 2023-09-30 | $-33.02M | (m) | (m) | $19.44M | (m) | (m) |
| 2023-06-30 | $-34.13M | (m) | (m) | $19.30M | (m) | (m) |
| 2023-03-31 | $-32.51M | (m) | (m) | $17.48M | (m) | (m) |
| 2022-12-31 | $-34.41M | $11.96M | (m) | $17.65M | (m) | -287.85% |
| 2022-09-30 | $-38.95M | (m) | (m) | $18.82M | (m) | (m) |
| 2022-06-30 | $-38.59M | (m) | (m) | $16.19M | (m) | (m) |
| 2022-03-31 | $-43.70M | (m) | (m) | $17.61M | (m) | (m) |
| 2021-12-31 | $-40.71M | (m) | (m) | $15.08M | (m) | (m) |
| 2021-09-30 | $-35.05M | (m) | (m) | $11.50M | (m) | (m) |
| 2021-06-30 | $-30.89M | (m) | (m) | $9.71M | (m) | (m) |
| 2021-03-31 | $-27.76M | (m) | (m) | $7.25M | (m) | (m) |
| 2020-12-31 | $-26.65M | $9.38M | (m) | $6.41M | (m) | -283.93% |
| 2020-09-30 | $-27.30M | $8.32M | (m) | $5.90M | (m) | -328.32% |
| 2020-06-30 | $-28.66M | $6.52M | (m) | $5.69M | (m) | -439.75% |
| 2020-03-31 | $-30.83M | $5.05M | (m) | $5.98M | (m) | -609.92% |
| 2019-12-31 | $-28.95M | $5.78M | (m) | $5.82M | (m) | -501.24% |
| 2019-09-30 | $-35.23M | $5.86M | (m) | $5.74M | (m) | -600.86% |
| 2019-06-30 | $-35.01M | $6.02M | (m) | $5.91M | (m) | -581.30% |
| 2019-03-31 | $-31.47M | $5.20M | (m) | $5.82M | (m) | -605.03% |
| 2018-12-31 | $-30.82M | $4.42M | (m) | $5.15M | (m) | -697.98% |
| 2018-09-30 | $-39.39M | $4.36M | (m) | $5.08M | (m) | -903.07% |
| 2018-06-30 | $-40.23M | $4.33M | (m) | $4.45M | (m) | -928.97% |
| 2018-03-31 | $-35.50M | $4.34M | (m) | $3.77M | (m) | -817.38% |
| 2017-12-31 | $-34.25M | $4.36M | (m) | $4.27M | (m) | -785.27% |
| 2017-09-30 | $-16.88M | $2.85M | (m) | $4.57M | (m) | -592.69% |
| 2017-06-30 | $-12.72M | $1.80M | (m) | $5.68M | (m) | -707.32% |
| 2017-03-31 | $-13.78M | $925.79K | (m) | $6.71M | (m) | -1488.12% |
| 2016-12-31 | $-13.59M | $141.52K | (m) | $7.21M | (m) | -9599.84% |
| 2016-09-30 | $-14.11M | (m) | (m) | $7.73M | (m) | (m) |
| 2016-06-30 | $-13.69M | $195.14K | (m) | $7.01M | (m) | -7015.98% |
| 2016-03-31 | $-13.45M | $234.14K | (m) | $6.80M | (m) | -5744.93% |
| 2015-12-31 | $-12.45M | $258.38K | (m) | $6.48M | (m) | -4816.67% |
| 2015-09-30 | (m) | (m) | (m) | $1.17M | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | $1.05M | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | $-6.57K | (m) | (m) |
| 2014-12-31 | $-8.32M | $0.00 | (m) | $4.22M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |